Landmark Advances and New Dimensions in Osteoporosis Research

WebCAST CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

November 5, 2008

Expiration Date:

November 5, 2010

Intended Audience:

• Family medicine specialists
• Bone metabolism experts
• Preventive medicine specialists
• Gynecologists
• Nurse practitioners
• Orthopedic surgeons
• Consulting pharmacists
• Internal medicine specialists
• Endocrinologists
• Women's health physicians
• Geriatric nurse practitioners
• Rheumatologists

Grantor Support:

Supported by an independent educational
grant from Roche Pharmaceuticals and
GlaxoSmithKline.

Registration:

Enrollment for this course is complimentary, and clinicians are invited to view this CME-certified webcast and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

This activity has been planned and implemented in ac cordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massa chusetts Medical School (UMMS) and CMEducation Re sources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

The UMMS designates this continuing medical education activity for a maximum of 2.5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectiv ity and scientific rigor in all activities. All faculty partici pating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relation ships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty:

Program Chairman and Moderator
Mone Zaidi, MD, PhD, FRCP, FACP
Professor of Medicine and Physiology
Director, Mount Sinai Bone Program
Mount Sinai School of Medicine
New York, NY

Paul D. Miller, MD
Clinical Professor of Medicine
University of Colorado Health Sciences Center
Colorado Medical Director
Colorado Center for Bone Research
Lakewood, Colorado

Steven Harris, MD
Clinical Professor of Medicine
University of California, San Francisco
Chief, Osteoporosis Clinic
University of California, San Francisco
San Francisco, California

Faculty Disclosures:

Mone Zaidi, MD, PhD, FRCP
Grants/research support: Procter and Gamble Pharmaceuticals, IRIS (Paris) and Genzyme Corporation
Speaker's Bureau: Alliance for Better Bone Health, Procter and Gamble, Sanofi-Aventis Pharmaceuticals, Novartis, Merck, Roche, GlaxoSmithKline

Paul D. Miller, MD
Consultant: Amgen, Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, NPS, Procter & Gamble Pharmaceuticals, Roche, and Sanofi Pasteur.
Scientific grants: Amgen, Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Pharmacia, Procter & Gamble Pharmaceuticals, Roche, and Sanofi Pasteur

Steven Harris, MD
Consultant: Amgen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Procter & Gamble Pharmaceuticals, Roche, sanofi-aventis, and Wyeth Pharmaceuticals. Speaker’s Bureau: Eli Lilly, GlaxoSmithKline, Merck, Novartis, Procter & Gamble Pharmaceuticals, Roche, sanofi-aventis, and Wyeth Pharmaceuticals

Educational Objectives:

Participants will:

• Learn how recent advances in basic and clinical re search have helped to advance strategies for osteoporo sis management.
• Learn how to evaluate recent clinical trials in osteoporosis and how to apply the results of these trials to optimize man agement of patients with postmenopausal osteoporosis.
• Learn to analyze concepts, strategies, and findings ema nating from basic research studies in osteoporosis—at the cellular level involving ligands, osteoclastic activation, cell-cell interactions—and determine directions for future research and trial design.
• Learn to analyze concepts, strategies, and findings ema nating from clinical research studies in osteoporosis—at the level of BMD, regimen adherence and persistence, dose and dosing frequency—and determine directions for future research and trial design, and possible implications for clinical practice.
• Learn evidence-based approaches to reducing pro gression of osteoporosis, and reducing risk of fracture complications based on finding reported in the latest clinical research.
  
  

Disclaimer:

Copyright © 2008 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2008 All rights reserved